15,385 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Trueblood Wealth Management LLC

Trueblood Wealth Management LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,385 shares of the biopharmaceutical company’s stock, valued at approximately $443,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. RB Capital Management LLC lifted its stake in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. lifted its stake in Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after buying an additional 400 shares in the last quarter. United Bank lifted its stake in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares in the last quarter. Ergoteles LLC lifted its stake in Pfizer by 136.3% in the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after buying an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its stake in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after purchasing an additional 79,887 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Barclays dropped their price objective on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a report on Thursday, December 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Friday, March 1st. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. UBS Group lowered their target price on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Finally, Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Price Performance

Shares of PFE stock traded down $0.03 during trading hours on Thursday, reaching $27.75. The company’s stock had a trading volume of 39,637,859 shares, compared to its average volume of 43,829,785. The firm’s 50 day simple moving average is $27.47 and its 200-day simple moving average is $29.47. The company has a market capitalization of $157.14 billion, a price-to-earnings ratio of 77.25, a PEG ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $42.22. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period last year, the company earned $1.14 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.